Full Title
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple MyelomaPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.
Protocol
26-189
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07075185
ClinicalTrials.gov